<ul>
<li><strong>Cerapro® 是一種獲得專利的皮膚 pH 值降低霜，已根據歐洲醫療器械法規（CE 標誌）批准用於治療特應性皮炎。</strong></li>
<li><strong>產品計劃於 2026 年在包括瑞士、奧地利、荷蘭和比利時在內的六個歐洲市場推出。</strong></li>
</ul>
<p>, /PRNewswire/ -- Hyphens Pharma International Limited（&#34; <strong>Hyphens Pharma</strong>&#34;，或稱&#34; <strong>公司</strong>&#34;，與其子公司合稱為&#34; <strong>集團</strong>&#34;），新加坡領先的專業製藥和消費者醫療保健集團，欣然宣佈已授予 Louis Widmer SA（&#34; <strong>Louis Widmer</strong>&#34;）商業化其創新產品 Cerapro® MED 皮膚屏障霜的權利，簽署了一項涵蓋瑞士、列支敦士登、奧地利、比利時、盧森堡和荷蘭六個歐洲國家的許可、供應和商業化協議（&#34; <strong>外部許可協議</strong>&#34;）。</p>
<p>根據與 Louis Widmer 的外部許可協議，Hyphens Pharma 將獲得一次性費用和銷售的常規版税。</p>
<p>特應性皮炎是一種常見的濕疹形式，影響各個年齡段的數百萬人。皮膚 pH 值升高和皮膚屏障功能受損是導致這種皮膚狀況的主要因素。Cerapro®憑藉其專利配方，降低皮膚 pH 值並幫助恢復皮膚屏障。作為根據嚴格的歐洲醫療器械法規（MDR）獲得 CE 標誌的醫療器械，Cerapro®為濕疹患者提供了一種新穎的治療選擇。降低皮膚 pH 值也支持皮膚固有的抗微生物防禦系統。</p>
<p>在此次合作中，Louis Widmer 是一家總部位於瑞士的國際化妝品和製藥公司，自 1960 年以來以高質量的皮膚病產品而聞名，將在約定市場中商業化和推廣 Cerapro®給皮膚科醫生和兒科醫生。這一合作反映了兩家公司共同的願景，即提供以科學為基礎的產品，以改善患者的治療效果。</p>
<p>&#34; <em>與 Louis Widmer 的這一里程碑式合作伙伴關係彰顯了我們對創新和患者護理的承諾，</em>&#34; Hyphens Pharma 董事長兼首席執行官 Lim See Wah 表示。<em>&#34;通過利用 Louis Widmer 在皮膚科的強大影響力和專業知識，我們旨在將 Cerapro®帶給歐洲的患者，同時繼續探索新的增長機會。</em>&#34;</p>
<p>&#34; <em>我們很高興與 Hyphens Pharma 合作，將 Cerapro®引入我們的市場，為患者提供經過臨牀驗證的特應性皮炎解決方案。</em> <em>Cerapro®將成為我們 Remederm 系列的新旗艦，該系列在歐洲的專業零售商和醫生中都是乾燥、非常乾燥和特應性皮膚護理的領導者。</em> _&#34; Louis Widmer 的首席執行官 Annemarie Widmer 説道。</p>
<p><strong>關於 Hyphens Pharma International Limited</strong></p>
<p>Hyphens Pharma International Limited 及其子公司（&#34;集團&#34;）是新加坡領先的專業製藥和消費者醫療保健集團，秉持着每個人都應享有更好生活質量的信念。</p>
<p>集團總部位於新加坡，在馬來西亞、越南、印度尼西亞和菲律賓設有直接業務，並在泰國、柬埔寨、文萊、孟加拉國、緬甸、香港特別行政區和阿曼等地拓展業務。其五個主要實體——Hyphens Pharma、DocMed Technology、Ocean Health、Novem 和 Ardence Aesthetics，共同推進三個核心業務領域：製藥與醫療美容、專有品牌以及數字平台與電子藥房。</p>
<p>除了通過與全球品牌主要公司的獨家合作伙伴關係在選定的東盟市場營銷和分銷專業製藥產品外，集團還開發和商業化專有的皮膚病和健康補充產品。集團的綜合生態系統擴展到醫療超市和數字藥房平台，實現無縫的處方履行和直接向患者的藥物配送，為醫療保健提供者提供便利。</p>
<p>更多信息請訪問 www.hyphensgroup.com。</p>
<p><strong>關於 Louis Widmer SA</strong></p>
<p>Louis Widmer SA 是一家來自瑞士的國際化妝品和製藥公司。這家家族企業總部位於蘇黎世附近，以其高質量的護膚和皮膚病產品而聞名。自 1960 年成立以來，Louis Widmer 致力於可持續發展和創新。</p>
<p>他們通過開發、生產和分銷藥品和皮膚藥妝產品而脱穎而出。其主要專業領域包括乾燥皮膚、痤瘡、色素障礙、傷口癒合、抗衰老和防曬等多個方面。</p>
<p>更多信息請訪問 www.louis-widmer。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>代表發佈</td>
<td>:</td>
<td><strong>Hyphens Pharma International Limited</strong></td>
</tr>
<tr>
<td>媒體諮詢請聯繫</td>
<td>:</td>
<td>Ms Karina Choo / Mr Gerald Woon / Ms Chong Yi Sze</td>
</tr>
<tr>
<td>郵箱 / DID / 手機</td>
<td>:</td>
<td>[email protected] / (65) 6704 9280 / (65) 9107 6991</td>
</tr>
<tr>
<td></td>
<td></td>
<td>[email protected] / (65) 6704 9268 / (65) 9694 8364<br/>[email protected] / (65) 9729 6694</td>
</tr>
</tbody>
</table>
<p><em>本媒體發佈已由公司的贊助商 SAC Capital Private Limited（&#34;贊助商&#34;）審核。它未經過新加坡交易所證券交易有限公司（&#34;SGX-ST&#34;）的審查或批准，SGX-ST 對本媒體發佈的內容不承擔任何責任，包括對本媒體發佈中所作的任何聲明或意見的正確性。</em></p>
<p><em>贊助商的聯繫人是 Ms Lee Khai Yinn（電話：（65）6232 3210），地址：新加坡羅賓遜路 1 號，#21-01 AIA 大廈，郵政編碼 048542。</em></p>
<p>來源 Hyphens Pharma International Limited</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTA1Jk5ld3NJdGVtSWQ9Q041NjAwMiZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMDUwNDMwUFJfTkVXU19VU1BSX19fX19DTjU2MDAy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTA1Jk5ld3NJdGVtSWQ9Q041NjAwMiZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMDUwNDMwUFJfTkVXU19VU1BSX19fX19DTjU2MDAy"/></p>

凱帆藥劑國際

<p>凱帆藥劑國際已將其 Cerapro® MED 皮膚屏障霜授權給 Louis Widmer SA，在包括瑞士和比利時在內的六個歐洲國家進行商業化。該產品已獲得 CE 標誌認證，作為治療特應性皮炎的醫療器械，計劃於 2026 年上市。凱帆藥劑將獲得預付款和銷售提成。此次合作旨在利用 Louis Widmer 在皮膚病學方面的專業知識，以改善歐洲患者的治療效果</p>

<ul>
<li><strong>Cerapro® is a patented, skin pH-lowering cream approved for the treatment of atopic dermatitis under the European</strong> <strong>Medical Device Regulation (</strong> <strong>CE Mark)</strong></li>
<li><strong>Product launch targeted for 2026 in six European markets, including Switzerland, Austria, the Netherlands and Belgium.</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>Cerapro® 是一種獲得專利的皮膚 pH 值降低霜，已根據歐洲醫療器械法規（CE 標誌）批准用於治療特應性皮炎。</strong></li>
<li><strong>產品計劃於 2026 年在包括瑞士、奧地利、荷蘭和比利時在內的六個歐洲市場推出。</strong></li>
</ul>
</div><p>, /PRNewswire/ -- Hyphens Pharma International Limited (&#34; <strong>Hyphens Pharma</strong>&#34;, or the &#34; <strong>Company</strong>&#34;, and together with its subsidiaries, the &#34; <strong>Group</strong>&#34;), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that it has granted the rights to commercialise its innovative product, Cerapro® MED Skin Barrier Cream, to Louis Widmer SA (&#34; <strong>Louis Widmer</strong>&#34;) via a licensing, supply and commercialisation agreement (&#34; <strong>Out-Licensing Agreement</strong>&#34;) that covers six European countries, namely Switzerland, Liechtenstein, Austria, Belgium, Luxembourg and the Netherlands.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Hyphens Pharma International Limited（&#34; <strong>Hyphens Pharma</strong>&#34;，或稱&#34; <strong>公司</strong>&#34;，與其子公司合稱為&#34; <strong>集團</strong>&#34;），新加坡領先的專業製藥和消費者醫療保健集團，欣然宣佈已授予 Louis Widmer SA（&#34; <strong>Louis Widmer</strong>&#34;）商業化其創新產品 Cerapro® MED 皮膚屏障霜的權利，簽署了一項涵蓋瑞士、列支敦士登、奧地利、比利時、盧森堡和荷蘭六個歐洲國家的許可、供應和商業化協議（&#34; <strong>外部許可協議</strong>&#34;）。</p>
</div><p>In accordance with the Out-Licensing Agreement with Louis Widmer, Hyphens Pharma will receive an upfront fee and customary royalties on sales.</p>
<div class="lb-trans"><p>根據與 Louis Widmer 的外部許可協議，Hyphens Pharma 將獲得一次性費用和銷售的常規版税。</p>
</div><p>Atopic dermatitis, a common form of eczema, affects millions across all age groups. Elevated skin pH and impaired skin barrier function are key drivers of this skin condition. Cerapro®, with its patented formulation, lowers skin pH and helps restore the skin barrier. Approved as a CE-marked medical device under the stringent European Medical Device Regulation (MDR), Cerapro® offers a novel treatment option for patients with eczema. Lowering skin pH also supports the skin's inherent antimicrobial defence system.</p>
<div class="lb-trans"><p>特應性皮炎是一種常見的濕疹形式，影響各個年齡段的數百萬人。皮膚 pH 值升高和皮膚屏障功能受損是導致這種皮膚狀況的主要因素。Cerapro®憑藉其專利配方，降低皮膚 pH 值並幫助恢復皮膚屏障。作為根據嚴格的歐洲醫療器械法規（MDR）獲得 CE 標誌的醫療器械，Cerapro®為濕疹患者提供了一種新穎的治療選擇。降低皮膚 pH 值也支持皮膚固有的抗微生物防禦系統。</p>
</div><p>Under this collaboration, Louis Widmer, a Swiss-based international cosmetics and pharmaceuticals company renowned for high-quality dermatology products since 1960, will commercialise and promote Cerapro® to dermatologists and paediatricians in the agreed markets. This collaboration reflects the shared vision of both companies to deliver science-backed products that enhance patient outcomes.</p>
<div class="lb-trans"><p>在此次合作中，Louis Widmer 是一家總部位於瑞士的國際化妝品和製藥公司，自 1960 年以來以高質量的皮膚病產品而聞名，將在約定市場中商業化和推廣 Cerapro®給皮膚科醫生和兒科醫生。這一合作反映了兩家公司共同的願景，即提供以科學為基礎的產品，以改善患者的治療效果。</p>
</div><p>&#34; <em>This milestone partnership with Louis Widmer underscores our commitment to innovation and patient care,&#34;</em> said Mr Lim See Wah, Chairman and CEO of Hyphens Pharma. <em>&#34;By leveraging Louis Widmer's strong presence and expertise in dermatology, we aim to bring Cerapro® to patients in Europe while continuing to explore new growth opportunities.&#34;</em></p>
<div class="lb-trans"><p>&#34; <em>與 Louis Widmer 的這一里程碑式合作伙伴關係彰顯了我們對創新和患者護理的承諾，</em>&#34; Hyphens Pharma 董事長兼首席執行官 Lim See Wah 表示。<em>&#34;通過利用 Louis Widmer 在皮膚科的強大影響力和專業知識，我們旨在將 Cerapro®帶給歐洲的患者，同時繼續探索新的增長機會。</em>&#34;</p>
</div><p>&#34; <em>We are excited to partner with Hyphens Pharma to introduce Cerapro® to our markets, offering patients a clinically proven solution for atopic dermatitis.</em> <em>Cerapro® will be the new flagship of our Remederm line, which is a leader in Europe in both specialist retailers and doctors for the care of dry, very dry and atopic skin.</em> <em>,</em>&#34; said Ms Annemarie Widmer, CEO of Louis Widmer.</p>
<div class="lb-trans"><p>&#34; <em>我們很高興與 Hyphens Pharma 合作，將 Cerapro®引入我們的市場，為患者提供經過臨牀驗證的特應性皮炎解決方案。</em> <em>Cerapro®將成為我們 Remederm 系列的新旗艦，該系列在歐洲的專業零售商和醫生中都是乾燥、非常乾燥和特應性皮膚護理的領導者。</em> _&#34; Louis Widmer 的首席執行官 Annemarie Widmer 説道。</p>
</div><p><strong>About Hyphens Pharma International Limited</strong></p>
<div class="lb-trans"><p><strong>關於 Hyphens Pharma International Limited</strong></p>
</div><p>Hyphens Pharma International Limited and its subsidiaries (the &#34;Group&#34;) is Singapore's leading specialty pharmaceutical and consumer healthcare group, driven by the belief that everyone deserves access to a better quality of life.</p>
<div class="lb-trans"><p>Hyphens Pharma International Limited 及其子公司（&#34;集團&#34;）是新加坡領先的專業製藥和消費者醫療保健集團，秉持着每個人都應享有更好生活質量的信念。</p>
</div><p>From its headquarters in Singapore, it maintains a direct presence in Malaysia, Vietnam, Indonesia and the Philippines, with extended reach into Thailand, Cambodia, Brunei, Bangladesh, Myanmar, Hong Kong S.A.R. and Oman. Its five key entities — Hyphens Pharma, DocMed Technology, Ocean Health, Novem, and Ardence Aesthetics, collectively advance three core business areas: Pharmaceuticals &amp; Medical Aesthetics, Proprietary Brands, and Digital Platform &amp; E-Pharmacy.</p>
<div class="lb-trans"><p>集團總部位於新加坡，在馬來西亞、越南、印度尼西亞和菲律賓設有直接業務，並在泰國、柬埔寨、文萊、孟加拉國、緬甸、香港特別行政區和阿曼等地拓展業務。其五個主要實體——Hyphens Pharma、DocMed Technology、Ocean Health、Novem 和 Ardence Aesthetics，共同推進三個核心業務領域：製藥與醫療美容、專有品牌以及數字平台與電子藥房。</p>
</div><p>Beyond marketing and distributing specialty pharmaceutical products across selected ASEAN markets through exclusive partnerships with global brand principals, the Group develops and commercialises proprietary dermatological and health supplement products. The Group's integrated ecosystem extends to a medical hypermart and digital pharmacy platform, enabling seamless prescription fulfillment and direct-to-patient medication delivery for healthcare providers.</p>
<div class="lb-trans"><p>除了通過與全球品牌主要公司的獨家合作伙伴關係在選定的東盟市場營銷和分銷專業製藥產品外，集團還開發和商業化專有的皮膚病和健康補充產品。集團的綜合生態系統擴展到醫療超市和數字藥房平台，實現無縫的處方履行和直接向患者的藥物配送，為醫療保健提供者提供便利。</p>
</div><p>More information is available at www.hyphensgroup.com.</p>
<div class="lb-trans"><p>更多信息請訪問 www.hyphensgroup.com。</p>
</div><p><strong>About Louis Widmer SA</strong></p>
<div class="lb-trans"><p><strong>關於 Louis Widmer SA</strong></p>
</div><p>Louis Widmer SA is an international cosmetics and pharmaceuticals company from Switzerland. The family company, with its head office near Zurich, is known for its high-quality skin care and dermatology products. Since it was founded in 1960, Louis Widmer has dedicated itself to sustainability and innovation.</p>
<div class="lb-trans"><p>Louis Widmer SA 是一家來自瑞士的國際化妝品和製藥公司。這家家族企業總部位於蘇黎世附近，以其高質量的護膚和皮膚病產品而聞名。自 1960 年成立以來，Louis Widmer 致力於可持續發展和創新。</p>
</div><p>They distinguish themselves by developing, producing, and distributing both pharmaceutical and dermocosmetic products. Their main areas of expertise include dry skin, acne, pigmentation disorders, wound healing, anti-aging, and sun protection, among many others.</p>
<div class="lb-trans"><p>他們通過開發、生產和分銷藥品和皮膚藥妝產品而脱穎而出。其主要專業領域包括乾燥皮膚、痤瘡、色素障礙、傷口癒合、抗衰老和防曬等多個方面。</p>
</div><p>More information is available at www.louis-widmer.</p>
<div class="lb-trans"><p>更多信息請訪問 www.louis-widmer。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Issued on behalf of</td>
<td>:</td>
<td><strong>Hyphens Pharma International Limited</strong></td>
</tr>
<tr>
<td>For media enquires contact</td>
<td>:</td>
<td>Ms Karina Choo / Mr Gerald Woon / Ms Chong Yi Sze</td>
</tr>
<tr>
<td>Email / DID / Mobile</td>
<td>:</td>
<td>[email protected] / (65) 6704 9280 / (65) 9107 6991</td>
</tr>
<tr>
<td></td>
<td></td>
<td>[email protected] / (65) 6704 9268 / (65) 9694 8364<br/>[email protected] / (65) 9729 6694</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>代表發佈</td>
<td>:</td>
<td><strong>Hyphens Pharma International Limited</strong></td>
</tr>
<tr>
<td>媒體諮詢請聯繫</td>
<td>:</td>
<td>Ms Karina Choo / Mr Gerald Woon / Ms Chong Yi Sze</td>
</tr>
<tr>
<td>郵箱 / DID / 手機</td>
<td>:</td>
<td>[email protected] / (65) 6704 9280 / (65) 9107 6991</td>
</tr>
<tr>
<td></td>
<td></td>
<td>[email protected] / (65) 6704 9268 / (65) 9694 8364<br/>[email protected] / (65) 9729 6694</td>
</tr>
</tbody>
</table>
</div><p><em>This media release has been reviewed by the Company's sponsor, SAC Capital Private Limited (the &#34;Sponsor&#34;). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the &#34;SGX-ST&#34;) and the SGX-ST assumes no responsibility for the contents of this media release, including the correctness of any of the statements or opinions made or reports contained in this media release.</em></p>
<div class="lb-trans"><p><em>本媒體發佈已由公司的贊助商 SAC Capital Private Limited（&#34;贊助商&#34;）審核。它未經過新加坡交易所證券交易有限公司（&#34;SGX-ST&#34;）的審查或批准，SGX-ST 對本媒體發佈的內容不承擔任何責任，包括對本媒體發佈中所作的任何聲明或意見的正確性。</em></p>
</div><p><em>The contact person for the Sponsor is Ms Lee Khai Yinn (Tel: (65) 6232 3210) at 1 Robinson Road, #21-01 AIA Tower, Singapore 048542.</em></p>
<div class="lb-trans"><p><em>贊助商的聯繫人是 Ms Lee Khai Yinn（電話：（65）6232 3210），地址：新加坡羅賓遜路 1 號，#21-01 AIA 大廈，郵政編碼 048542。</em></p>
</div><p>SOURCE Hyphens Pharma International Limited</p>
<div class="lb-trans"><p>來源 Hyphens Pharma International Limited</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTA1Jk5ld3NJdGVtSWQ9Q041NjAwMiZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMDUwNDMwUFJfTkVXU19VU1BSX19fX19DTjU2MDAy" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CN56002&amp;Transmission_Id=202601050430PR_NEWS_USPR_____CN56002&amp;DateId=20260105"/></p>

凱帆藥劑國際將 Cerapro® MED 皮膚屏障霜的許可授權給六個歐洲國家